Vision Sensing Acquisition Corp. Advances with CCT
Agrees to Terminate Previous Agreement with Mediforum Co., Ltd.
Overview of Convergence CT, Inc.
Convergence CT, Inc. ("CCT") is dedicated to developing technologies that effectively manage vast amounts of data to benefit patients, communities, healthcare providers, and researchers. The company focuses on creating smart hospital information systems and enhancing hospital workflows through proprietary technology and tailored solutions. By incorporating IoT and AI, CCT aims to improve patient care and contribute to global health insights.
Details of Vision Sensing Acquisition Corp.
Vision Sensing Acquisition Corp. ("VSAC") is a Special Purpose Acquisition Company (SPAC) listed on NASDAQ under the ticker symbol "VSAC." The company has confirmed that it will provide a total of US$135 million to CCT's shareholders. This includes an initial upfront equity transfer of US$110 million to current CCT shareholders, with the remaining amount contingent on performance-based earn-outs.
Termination of Previous Agreement
Vision Sensing Acquisition Corp. has reached a mutual decision with Mediforum Co., Ltd. to terminate the Agreement and Plan of Merger that was originally dated January 12, 2024. Both parties have acknowledged that finalizing the proposed transaction within a reasonable timeframe is not feasible and have agreed to waive any claims against each other.
New Letter of Intent with CCT
VSAC is pleased to announce a non-binding letter of intent with CCT, outlining plans for a business combination where VSAC intends to acquire 100% of CCT's outstanding equity. The specifics of the legal transaction structure, which may include pre-closing reorganization, will be determined collaboratively by both parties. The aim is to finalize the details of the business combination shortly.
CCT’s Innovative Approach
CCT is leading the way in integrating healthcare data, drawing on its 20 years of experience in optimizing hospital workflows. The organization seeks to empower health providers, life sciences companies, payers, and governments with essential global health insights through its proprietary technology. Following the transaction, the strong management team is expected to remain in place, and the combined entity is anticipated to list on NASDAQ under a new ticker symbol after closing.
Growth and Market Expansion
Leadership at CCT has expressed excitement about the merger with VSAC, highlighting the growth opportunities it presents in Asia and other global markets. As CCT expands into new regions, it believes its technological solutions will address the rising demand for innovative healthcare systems and positively influence profitability. The forthcoming NASDAQ listing is projected to improve access to capital for shareholders and enhance business valuation.
Transaction Details and Structure
According to the non-binding LOI, a new offshore company will be created to facilitate the merger between CCT and VSAC. The total transaction consideration for CCT's equity holders is set at US$135 million, structured on a cash-free and debt-free basis. An initial payment of US$110 million will be made upfront, with additional earn-out shares dependent on performance metrics after closing.
Governance and Board Composition
The board of directors for the surviving entity will consist of five directors, including three appointed by CCT and one by VSAC. To ensure compliance with NASDAQ regulations, the majority of board members will be independent.
Closing Conditions and Timeline
The completion of the business combination is subject to standard closing conditions, which include necessary audits and regulatory approvals. The parties aim to finalize a binding Business Combination Agreement by a designated target date.
About CCT and VSAC
Convergence CT, Inc. is focused on connecting technologies to manage healthcare data effectively. Its innovative smart hospital solutions leverage IoT and AI to enhance patient care. For further information about CCT, visit their official website.
Vision Sensing Acquisition Corp. is a dedicated SPAC established under relevant securities regulations, aiming to achieve a qualifying transaction. Additional details can be found on their official website.
Frequently Asked Questions
What is the significance of the agreement between VSAC and CCT?
This agreement paves the way for VSAC to acquire CCT, enhancing its ability to manage healthcare data and optimize hospital workflows.
How will the proposed business combination affect shareholders?
CCT shareholders will receive a total of US$135 million in consideration, with part of it linked to performance metrics after the transaction concludes.
What is the anticipated timeline for the business combination?
The parties aim to finalize a binding Business Combination Agreement within 45 days of the initial letter of intent.
Who will govern the new combined entity?
The board will consist of five directors, with the majority being independent in accordance with NASDAQ regulations.
What opportunities does this merger create?
The merger is expected to drive growth in Asia and enhance CCT's technological capabilities in the healthcare sector, benefiting patient care and operational efficiency.
